Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

(2021) Kristian Reich et al.   LANCET

Efficacy and safety of interleukin‐17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta‐analysis

(2021) Chongru He et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Bimekizumab versus Adalimumab in Plaque Psoriasis

(2021) Richard B. Warren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bimekizumab versus Secukinumab in Plaque Psoriasis

(2021) Kristian Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of IL-17-Producing Cells in Cutaneous Fungal Infections

(2021) Yu Sawada et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

(2021) Sophie Glatt et al.   JAMA Dermatology

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

(2020) Christopher T Ritchlin et al.   LANCET

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications

(2020) Esther von Stebut et al.   Frontiers in Immunology

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

(2020) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study

(2020) Yukie Yamaguchi et al.   JOURNAL OF DERMATOLOGY

Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study

(2020) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Oral epithelial IL-22/STAT3 signaling licenses IL-17–mediated immunity to oral mucosal candidiasis

(2020) Felix E. Y. Aggor et al.   Science Immunology

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

(2020) Ralph Adams et al.   Frontiers in Immunology

Course of Esophageal Candidiasis and Outcomes of Patients at a Single Center

(2018) Patrick Hoversten et al.   Clinical Gastroenterology and Hepatology

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

(2018) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Prevalence and Possible Role of Candida Species in Patients with Psoriasis: A Systematic Review and Meta-Analysis

(2018) Aldona Pietrzak et al.   MEDIATORS OF INFLAMMATION

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials

(2018) R G Langley et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Infections of the esophagus: an update on risk factors, diagnosis, and management

(2018) P Hoversten et al.   DISEASES OF THE ESOPHAGUS

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications

(2017) Leticia Monin et al.   Cold Spring Harbor Perspectives in Biology

A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis

(2016) April W. Armstrong et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study

(2016) K. Yamasaki et al.   BRITISH JOURNAL OF DERMATOLOGY

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

New therapies for psoriasis and psoriatic arthritis

(2016) Christopher T. Ritchlin et al.   CURRENT OPINION IN RHEUMATOLOGY

Risk Factors for Targeted Fungal and Mycobacterial Infections in Patients Taking Tumor Necrosis Factor Inhibitors

(2016) Elizabeth Salt et al.   Arthritis & Rheumatology

Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

(2015) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

(2015) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Immunological and histopathological characterization of cutaneous candidiasis

(2015) Tacito Graminha Campois et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

(2015) Ulrich Mrowietz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

(2014) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

(2014) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral candidiasis in patients with psoriasis: Correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment

(2013) Bruna Lavinas Sayed Picciani et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Oral Candida colonization and candidiasis in patients with psoriasis

(2012) Ahmad A. Bedair et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy

(2011) Markus Ruhnke et al.   MYCOSES

Oropharyngeal candidiasis in the era of antiretroviral therapy

(2010) George R. Thompson et al.   ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS

Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007)

(2009) S. A. Messer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis

(2009) Heather R. Conti et al.   JOURNAL OF EXPERIMENTAL MEDICINE